Safe, promising antitumor activity; objective response was achieved by 13 (29%) of 45 evaluable patients overall, 8 (67%) of 12 patients with genomic BRCA mutations, 33% of patients with PD-L1-positive cancers and 15% of patients with PD-L1-negative cancers. The gene discussed is CD274; the disease is cancer.